Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BioRestorative Therapies, Inc. (BRTX)
|
Add to portfolio |
|
|
|
| Price: |
$4.33
| | Metrics |
| OS: |
4.67
|
M
| |
|
|
| Market cap: |
$20.2
|
M
| |
|
|
|
Net cash:
|
$11.6
|
M
| |
$2.49
|
per share
|
|
EV:
|
$8.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.6 | 0.4 | 0.0 |
| Revenue growth | -40.8% | 17.1% | 37.0% | 122.8% | -94.2% | 51.2% | 24661.7% | -89.2% |
| Cost of goods sold | -3.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.2 | 0.0 |
| Gross profit | 3.4 | 0.1 | 0.1 | 0.1 | 0.0 | 0.4 | 0.2 | 0.0 |
| Gross margin | 4459.1% | 100.0% | 100.0% | 100.0% | 99.7% | 58.4% | 48.6% | 87.6% |
| Sales and marketing | 0.0 | 0.3 | 0.4 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 |
| Research and development | 0.9 | 1.7 | 1.5 | 2.2 | 2.9 | 2.1 | 1.4 | 1.6 |
| General and administrative | 1.9 | 6.5 | 5.9 | 6.2 | 4.9 | 5.3 | 3.6 | 3.0 |
| EBIT | -2.2 | -8.4 | -7.6 | -8.4 | -7.8 | -7.2 | -4.9 | -4.8 |
| EBIT margin | -2889.1% | -6486.2% | -6889.8% | -10338.6% | -21414.0% | -1140.1% | -1183.3% | -282873.2% |
| Pre-tax income | -11.3 | -14.6 | -12.5 | -9.4 | -8.6 | -7.9 | -5.6 | -5.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -11.3 | -14.6 | -12.5 | -9.4 | -8.6 | -7.9 | -5.6 | -5.8 |
| Net margin | -14639.9% | -11267.6% | -11277.3% | -11660.1% | -23755.4% | -1259.9% | -1343.2% | -342333.0% |
| |
| Diluted EPS | ($28.56) | ($0.66) | ($1.64) | ($1.74) | ($2.10) | ($3.20) | ($4.38) | ($0.35) |
| Shares outstanding (diluted) | 0.4 | 22.3 | 7.6 | 5.4 | 4.1 | 2.5 | 1.3 | 16.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|